ROIV Roivant Sciences Ltd
Company Analysis
Latest News
🔴 Roivant Sciences is trading 15.41% down in after-hours trading; no reliable catalyst identified
Roivant Sciences is trading 15.41% down at $34.53, with the after-hours reversal remaining unexplained. - Closed at $40.82 on September 11, 2026. - No...
Roivant Reports Positive Phase 2 Trial Data for Mosliciguat, Initiates Phase 3 Study
Roivant Sciences announced positive results from its Phase 2 PHocus clinical trial for mosliciguat in patients with pulmonary hypertension associated with...
🟢 Roivant Sciences is trading 13.46% up today after positive Phase 2 PHocus results
Roivant Sciences is trading 13.46% up now at $39.63 after positive Phase 2 PHocus results for mosliciguat in pulmonary hypertension associated with...
Roivant Surges 21% on Blockbuster Lung Drug Data — But Can a Phase 2 Win Sustain a $7 Billion Bet?
Shares of Roivant Sciences vaulted +21.2% to $42.33 this morning after the company disclosed what it called the strongest efficacy ever recorded in a...
🟢 Roivant Sciences surges 21% in pre-market on positive mosliciguat PHocus topline results
Roivant Sciences is trading at $42.33, up +21.19%, following the announcement of positive Phase 2 PHocus topline results for mosliciguat. The positive results...
Roivant Announces FDA Approval and Immediate Launch of LISRAYA™ for Dermatomyositis
Roivant Sciences announced that the U.S. Food and Drug Administration (FDA) has approved LISRAYA™ (brepocitinib) for the treatment of adults with...
🔴 Roivant Sciences is trading 4.07% down today
Roivant Sciences is trading 4.07% down at $36.05 after opening-day weakness on August 28, 2026. - The FDA approval of LISRAYA for adult dermatomyositis was...
Roivant Announces FDA Approval for LISRAYA™, a New Dermatomyositis Treatment
Roivant Sciences announced that the U.S. Food and Drug Administration (FDA) has approved LISRAYA™ (brepocitinib) for the treatment of adults with...
Roivant Secures FDA Approval for First Targeted Dermatomyositis Therapy
The U.S. Food and Drug Administration (FDA) approved LISRAYA (brepocitinib) for adults with dermatomyositis. Roivant Sciences' subsidiary, Priovant...
Roivant's Brepocitinib Clears Skin in Phase 3, Targeting 2026 FDA Approval
Priovant Therapeutics, a Roivant Sciences subsidiary, published skin-specific Phase 3 VALOR trial results for brepocitinib in JAMA Dermatology. The study...
Roivant's 7% Pop on a Narrower Loss and a Drug Launch Six Weeks Away — Is the Market Pricing in a Future That Hasn't Arrived?
Shares shifted as Roivant Sciences surged 7.2% to $38.80, a delayed reaction to first-quarter results reported August 6 and growing anticipation around a...
🟢 Roivant Sciences is trading 7% up in pre-market after narrower first-quarter loss
Roivant Sciences is trading 7.18% up now at $38.80 after investors reacted favorably to its narrower first-quarter loss despite weaker revenue. - August 6...
Roivant's first quarter EPS beats estimates on lower-than-expected loss, while its cash position remains strong at $3.9B.
Roivant Sciences reported a first quarter net loss of $0.26 per share, narrower than analyst expectations, on revenue of $1.4 million which missed estimates....
Roivant Sciences Ltd Q2 2026 Earnings Preview: What Analysts Expect on August 06, 2026
Roivant Sciences is projected to report a Q2 2026 revenue of approximately $2.00 million and a consensus EPS loss of -$0.45, while its current stock price of...
🟢 Roivant Sciences is trading 4.1% up today amid a broad biotech rally and risk-on sentiment
Roivant Sciences is trading 4.1% up at $34.68, outperforming recent sessions as a strong risk-on mood lifts the broader biotech sector. • The move follows...
🟢 Roivant Sciences is trading 4.2% up today amid a broad tech-led market rebound
Roivant Sciences is trading 4.2% up today at $34.27 amid a broad U.S. equity rebound led by technology stocks. • The move aligns with a wider market rally,...
🟢 Roivant Sciences is trading 4.9% up today after Q4 earnings beat and $770M Moderna settlement gain
Roivant Sciences is trading at $36.20 (+4.91%) in pre-market action after fiscal Q4 2026 results significantly beat analyst expectations due to a major...
Roivant's Genevant Sues Pfizer Globally, Escalating Multi-Billion Dollar Patent Fight
Roivant Sciences' subsidiary Genevant Sciences and Arbutus Biopharma filed three new patent infringement lawsuits against Pfizer and BioNTech. These filings in...
🔴 Roivant Sciences is trading 4.1% down today on sector-wide profit-taking
Roivant Sciences is trading 4.1% down at $34.51 as the broader biotech sector pulls back and investors take profits following a sharp rally. • The decline...
🔴 Roivant Sciences is trading 4.1% down today after a multi-week rally fueled by deal-related cash and index flows
Roivant Sciences is trading 4.1% down today at $35.29 as the stock pulls back following a multi-week rally fueled by deal-related cash inflows and index-driven...